E

    Exelixis Inc (EXEL)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $54.64
    +0.19 (+0.35%)

    Market Cap: $13.54B

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    90%(36/40)
    Avg Surprise
    +91.68%
    Streak
    9 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$0.91
    Range$0.79 - $0.96
    11 analysts
    EPS Revisions
    4
    0
    7d
    5
    3
    30d
    EPS Estimate Drift
    90d ago$0.90-0.2%
    60d ago$0.90-0.2%
    30d ago$0.89-2.4%
    7d ago$0.89-2.0%
    Current$0.91
    Revenue Consensus
    $652M
    Range$636M - $672M
    17 analysts
    Period ending Dec 31, 2026
    EPS Consensus$1.05
    Range$0.65 - $1.24
    12 analysts
    Revenue Consensus
    $658M
    Range$626M - $715M
    19 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$1.05---
    Sep 26EST
    		-$0.91---
    Jun 26
    Reported Aug 5
    		$0.82$0.75+9.33%Beat+9.3%
    Mar 26
    Reported May 5
    		$0.87$0.76+14.47%Beat+40.3%
    Dec 25
    Reported Feb 10
    		$0.94$0.81+16.05%Beat+70.9%
    Sep 25
    Reported Nov 4
    		$0.78$0.67+16.42%Beat+66.0%
    Jun 25
    Reported Jul 28
    		$0.75$0.65+15.38%Beat-10.7%
    Mar 25
    Reported May 13
    		$0.62$0.37+69.12%Beat+264.7%
    Dec 24
    Reported Feb 11
    		$0.55$0.49+12.24%Beat+66.7%
    Sep 24
    Reported Oct 29
    		$0.47$0.42+11.90%Beat+370.0%
    Jun 24
    Reported Aug 6
    		$0.84$0.37+127.03%Beat+171.0%
    Mar 24
    Reported Apr 30
    		$0.17$0.29-41.38%Miss+6.3%
    Dec 23
    Reported Feb 6
    		$0.33$0.31+6.45%Beat+1200.0%
    Sep 23
    Reported Nov 1
    		$0.10$0.19-47.37%Miss-67.7%
    Jun 23
    Reported Aug 1
    		$0.31$0.22+40.91%Beat+10.7%
    Mar 23
    Reported May 9
    		$0.16$0.22-27.27%Miss-38.5%
    Dec 22
    Reported Feb 7
    		$-0.03$-0.05+40.00%Beat-108.6%
    Sep 22
    Reported Nov 1
    		$0.31$0.24+29.17%Beat+55.0%
    Jun 22
    Reported Aug 9
    		$0.28$0.24+16.67%Beat-24.3%
    Mar 22
    Reported May 10
    		$0.26$0.23+13.04%Beat+188.9%
    Dec 21
    Reported Feb 17
    		$0.35$0.16+118.75%Beat+150.0%
    Sep 21
    Reported Nov 2
    		$0.20$0.27-25.93%Miss+400.0%
    Jun 21
    Reported Aug 5
    		$0.37$0.14+164.29%Beat+48.0%
    Mar 21
    Reported May 6
    		$0.09$0.09+0.00%Beat-52.6%
    Dec 20
    Reported Feb 10
    		$0.14$0.10+40.00%Beat-36.4%
    Sep 20
    Reported Nov 5
    		$0.04$0.04+0.00%Beat-88.2%
    Jun 20
    Reported Aug 6
    		$0.25$0.14+78.57%Beat-13.8%
    Mar 20
    Reported May 5
    		$0.19$0.17+11.76%Beat-20.8%
    Dec 19
    Reported Feb 25
    		$0.22$0.17+29.41%Beat-40.5%
    Sep 19
    Reported Oct 30
    		$0.34$0.22+54.55%Beat-17.1%
    Jun 19
    Reported Jul 31
    		$0.29$0.28+3.57%Beat+3.6%
    Mar 19
    Reported May 1
    		$0.24$0.24+0.00%Beat-35.1%
    Dec 18
    Reported Feb 12
    		$0.37$0.23+60.87%Beat+208.3%
    Sep 18
    Reported Nov 1
    		$0.41$0.17+141.18%Beat+57.7%
    Jun 18
    Reported Aug 1
    		$0.28$0.16+75.00%Beat+250.0%
    Mar 18
    Reported May 2
    		$0.37$0.15+146.67%Beat+640.0%
    Dec 17
    Reported Feb 26
    		$0.12$0.12+0.00%Beat+0.0%
    Sep 17
    Reported Nov 1
    		$0.26$0.07+271.43%Beat+2500.0%
    Jun 17
    Reported Aug 2
    		$0.08$0.03+166.67%Beat-
    Mar 17
    Reported May 1
    		$0.05$-0.01+600.00%Beat-
    Dec 16
    Reported Feb 27
    		$0.12$-0.01+1300.00%Beat-
    Sep 16
    Reported Nov 3
    		$0.01N/A+108.33%Beat-

    Key Metrics

    Valuation
    P/E Ratio16.02EV/EBITDA12.75x
    Price/FCF11.69xFCF Yield8.56%
    Profitability
    Profit Margin35.30%Operating Margin39.50%
    ROE44.40%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio3.46xQuick Ratio3.38x
    Trading Statistics
    Beta0.42Avg Volume2.59M
    52-Week High$57.5752-Week Low$33.76

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$54.70
    SMA 20$53.74
    SMA 50$54.55
    SMA 200$47.33
    EMA 10$54.58
    EMA 20$54.30
    EMA 50$53.68
    EMA 200$48.47

    MACD

    Line: 0.24Signal: 0.00Hist: 0.24

    ADX

    ADX: 17.3+DI: 21.3-DI: 26.8

    Aroon & PSAR

    Aroon Up28.0
    Aroon Down52.0
    PSAR$52.67

    Bollinger Bands

    Upper Band$57.63
    Lower Band$49.85
    %B Position1447%(Upper)
    Band Width0.62

    RSI (14-Day)

    Neutral
    51.7

    Momentum Oscillators

    Stoch %K69.5
    Stoch %D78.0
    Williams %R-32.6
    ROC (10d)4.4%
    Momentum2.32
    CCI (20d)30.8
    MFI (14d)58.5

    Volatility Measures

    ATR (14d)$1.55(2.8%)
    StdDev (20d)1.94
    Hist Vol42.5%(High)

    Volume Flow

    VWAP$54.36
    OBV-11.4M
    AD Line1.5M
    CMF (20d)0.098

    Volume Metrics

    Avg Vol (20d)2.5M
    Vol Ratio0.9x
    VWMA (20d)$53.69

    Pivot Points

    R3$56.22
    R2$55.74
    R1$55.09
    Pivot Point$54.61
    S1$53.96
    S2$53.48
    S3$52.83

    Advanced Oscillators

    TSI3.07
    Ultimate Osc60.2
    KST-15.49

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$628.69M$610.81M$598.66M$597.75M$568.26M$555.45M$566.75M$539.54M$637.18M$425.23M$479.65M$471.92M
    Cost of Revenue$20.66M$19.95M$26.48M$18.57M$19.47M$19.17M$19.96M$17.33M$17.67M$21.26M$21.75M$18.77M
    Gross Profit$608.03M$590.86M$572.18M$579.18M$548.79M$536.27M$546.79M$522.21M$619.51M$403.97M$457.90M$453.15M
    Operating Expenses$359.62M$339.52M$336.97M$342.64M$335.21M$349.42M$383.58M$386.14M$343.64M$374.51M$376.11M$470.73M
    R&D$211.99M$199.92M$213.25M$199.16M$200.36M$212.23M$249.00M$222.57M$211.15M$227.69M$244.67M$332.58M
    SG&A$147.63M$139.60M$123.02M$123.66M$134.86M$137.18M$134.33M$111.80M$132.01M$113.98M$131.44M$138.14M
    Operating Income$248.41M$251.34M$235.22M$236.54M$213.58M$186.86M$163.21M$136.07M$275.87M$29.46M$81.79M$-17,583,000
    Interest Income$14.21M$16.13M$17.43M$15.92M$16.79M$19.08M$21.30M$18.71M$17.26M$19.89M$21.39M$23.11M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$262.68M$267.69M$252.69M$252.41M$230.41M$205.69M$184.77M$154.75M$292.85M$49.27M$103.04M$5.82M
    Income Tax Expense$50.63M$57.22M$8.16M$58.84M$45.57M$46.07M$44.91M$36.78M$66.73M$11.95M$17.52M$4.78M
    Net Income$212.05M$210.47M$244.53M$193.58M$184.85M$159.62M$139.86M$117.97M$226.12M$37.32M$85.52M$1.04M
    EBITDA$255.45M$258.51M$242.21M$243.91M$220.97M$193.96M$171.12M$143.50M$282.92M$35.75M$88.18M$-10,998,000
    EBIT$248.47M$251.56M$235.26M$236.49M$213.63M$186.61M$163.48M$136.05M$275.59M$29.37M$81.65M$-17,294,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about EXEL

    News

    Exelixis Wins Appeal in Patent Case Against MSN Laboratories

    Exelixis has won an appeal in a patent case against MSN Laboratories. The article, published on August 31, 2026, reports on this legal victory without providing further details on the case itself. It also briefly mentions other recent news for Exelixis, including its Q2 2026 earnings call and revenue guidance.

    marketscreener.com•8/31/26•
    Bullish

    Exelixis Owners Keep Getting A Bigger Slice Of A Company In Transition

    Exelixis (EXEL) is increasing shareholder value through significant share buybacks, funded by the strong performance of its oncology drug, CABOMETYX. Despite a recent cut in revenue guidance, the company's free cash flow remains stable, supporting its buyback program. The future growth largely depends on the regulatory approval of its next potential franchise drug, zanzalintinib, which awaits a decision in December 2026.

    Trefis•8/24/26•
    Somewhat-Bullish

    BlackRock Inc. Purchases New Stake in Exelixis, Inc. $EXEL

    BlackRock Inc. has acquired a new 29.1 million-share stake in Exelixis (NASDAQ:EXEL), valued at approximately $1.58 billion, representing 11.57% of the biotechnology company. Institutional investors now own 85.27% of EXEL, which recently reported strong quarterly earnings of $0.91 EPS, beating estimates, though revenue was slightly below expectations. Despite insiders selling shares, analysts generally maintain a "Hold" rating with an average price target of $50.07 for Exelixis.

    MarketBeat•8/21/26•
    Neutral

    NFJ Investment Group LLC Makes New $18.39 Million Investment in Exelixis, Inc. $EXEL

    NFJ Investment Group LLC has acquired a new stake of 338,045 shares in Exelixis, Inc. (NASDAQ:EXEL) worth approximately $18.39 million during the second quarter, bringing institutional ownership in the biotechnology company to 85.27%. This investment comes as Exelixis reported strong quarterly earnings, beating analyst estimates with $0.91 EPS and 10.6% year-over-year revenue growth. Despite a "Hold" consensus rating, analysts have recently raised price targets, reflecting a mixed but generally optimistic outlook for the company whose stock opened near its 52-week high.

    MarketBeat•8/21/26•
    Bullish

    51,642 Shares in Exelixis, Inc. $EXEL Purchased by NewEdge Wealth LLC

    NewEdge Wealth LLC acquired a new stake of 51,642 shares in Exelixis, Inc. (NASDAQ:EXEL) during the second quarter, valued at approximately $2.81 million. Several other institutional investors also made new investments in the biotechnology company. Exelixis recently reported strong quarterly earnings, beating analyst estimates, and has an average "Hold" rating from analysts with an average price target of $50.07.

    MarketBeat•8/21/26•
    Somewhat-Bullish

    Frequently Asked Questions About EXEL

    Does EXEL pay dividends?
    Exelixis Inc (EXEL) does not currently pay a regular dividend.
    What is EXEL's P/E ratio?
    Exelixis Inc has a price-to-earnings (P/E) ratio of 16.02.
    What is EXEL's market cap?
    Exelixis Inc (EXEL) has a market capitalization of $13.54B with a current stock price of $54.64.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In